TCGA-71-8520-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- TGF_BETA_SIGNALING+0.380
- ANGIOGENESIS+0.320
- HEDGEHOG_SIGNALING+0.320
- NOTCH_SIGNALING+0.310
- COAGULATION+0.300
- MITOTIC_SPINDLE+0.270
- GLYCOLYSIS+0.240
- PROTEIN_SECRETION+0.240
Top 10 suppressed
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.410
- OXIDATIVE_PHOSPHORYLATION-0.350
- ALLOGRAFT_REJECTION-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.290
- E2F_TARGETS-0.260
- G2M_CHECKPOINT-0.250
- MTORC1_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.220
- SPERMATOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.799 |
| 2 | TCGA-44-6775-01A-11R-1858-07 | — | cohortA1 | 0.763 |
| 3 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.762 |
| 4 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.760 |
| 5 | TCGA-97-7554-01A-11R-2039-07 | — | cohortA1 | 0.750 |
| 6 | SRR2932823 | — | — | 0.747 |
| 7 | 52a10f37-ee39-4805-908e-b9e35fa983e9 | — | — | 0.738 |
| 8 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.736 |
| 9 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.735 |
| 10 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |